
==== Front
Eur J Nutr
Eur J Nutr
European Journal of Nutrition
1436-6207
1436-6215
Springer Berlin Heidelberg Berlin/Heidelberg

38703228
3394
10.1007/s00394-024-03394-y
Original Contribution
Long-term effects of an egg-protein hydrolysate on cognitive performance and brain vascular function: a double-blind randomized controlled trial in adults with elevated subjective cognitive failures
http://orcid.org/0009-0003-9749-0404
Adams Micah S.
http://orcid.org/0000-0002-8908-3580
Mensink Ronald P.
http://orcid.org/0000-0002-1570-9608
Plat Jogchum
http://orcid.org/0000-0001-6852-5776
Joris Peter J. p.joris@maastrichtuniversity.nl

https://ror.org/02jz4aj89 grid.5012.6 0000 0001 0481 6099 Department of Nutrition and Movement Sciences, NUTRIM Institute of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center+, Universiteitssingel 50, P.O. Box 616, 6200 MD Maastricht, The Netherlands
4 5 2024
4 5 2024
2024
63 6 20952107
7 2 2024
16 4 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Purpose

Short-term intake of the egg-protein hydrolysate Newtricious (NWT)-03 improved executive function, but underlying mechanisms and long-term effects, including other cognitive domains, are unknown.

Methods

A 36-week randomized controlled trial involving 44 overweight/obese individuals experiencing elevated Subjective Cognitive Failures (SCF; aged 60–75 years) assessed the impact of daily consumption of 5.7 g of NWT-03 or placebo powders on cognitive performance (psychomotor speed, executive function, memory) and Cerebral Blood Flow (CBF), a marker of brain vascular function. Cognitive performance was evaluated using a neurophysiological test battery (CANTAB) and CBF was measured using magnetic resonance imaging perfusion method Arterial Spin Labeling (ASL). Serum samples were collected to determine brain-derived neurotrophic factor (BDNF) concentrations.

Results

Anthropometrics, and energy and nutrient intakes remained stable throughout the trial. NWT-03 was well tolerated, and compliance was excellent (median: 99%; range: 87–103%). No overall intervention effects were observed on cognitive performance or CBF, but post-hoc analyses revealed significant improvements on executive function in women, but not men. Specifically, a reduction of 74 ms in reaction latency on the multitasking task (95% CI: −134 to −15; p = 0.02), a reduction of 9 between errors (95%CI: −14 to −3; p < 0.001), and a reduction of 9 total errors (95%CI: −15 to −3; p < 0.001) on the spatial working memory task were found in women. No intervention effects were observed on serum BDNF concentrations (p = 0.31).

Conclusion

Long-term consumption of NWT-03 improved multitasking abilities and working memory in women with elevated SCF. Brain vascular function remained unaffected. Sex differences in executive function require additional clarification.

Supplementary Information

The online version contains supplementary material available at 10.1007/s00394-024-03394-y.

Keywords

Brain vascular function
Cerebral blood flow
Cognitive performance
Egg-protein hydrolysates
Subjective cognitive failures
http://dx.doi.org/10.13039/100016036 Health~Holland Newtricious R&Dissue-copyright-statement© Springer-Verlag GmbH Germany, part of Springer Nature 2024
==== Body
pmcIntroduction

People with elevated Subjective Cognitive Failures (SCF), which are defined as the self-awareness of having brief failures in memory, perception, and/or action causing errors [1, 2], may be indicative of an increased risk of developing dementia [3]. Increased attention has been drawn to dietary interventions as a means to limit the progression of cognitive decline and to prevent the long-term development of dementia [4]. In fact, there are already indications that long-term dietary protein and protein hydrolysate intake improves cognitive performance, particularly in attention and psychomotor speed [5–10] and on executive function domains [7, 11–16]. Moreover, evidence already exists for the beneficial effects of egg-protein hydrolysates on cognitive performance. For instance, Mohajeri and colleagues have revealed in their study involving middle-aged women that 1.0 g/day of a tryptophan-rich egg-protein hydrolysate for 19 days improved executive function based on the Go/No-Go task [7]. Furthermore, the effects of Newtricious (NWT-03), another egg-protein hydrolysate derived from lysozyme hydrolysis from egg whites, were recently evaluated [17]. In a 4-week intervention trial in men and women with metabolic syndrome, we have shown that daily intake of 5.0 g NWT-03 also improved cognitive performance in the executive function domain based on the anti-cue reaction time task [18], with no effects on psychomotor speed.

The mechanisms underlying the observed improvements in cognitive performance after consuming protein hydrolysates are not well understood. Some suggestions indicate that NWT-03 may enhance peripheral vascular function [19] and cardiometabolic risk markers [20]. However, it is unknown if these effects translate to the brain, as impaired brain vascular function is considered an important mechanism preceding the development of an impaired cognitive performance [21, 22]. Previous randomized controlled trials (RCTs) have reported that dietary protein and protein hydrolysate interventions may enhance brain vascular function, as evidenced by improvements in cerebral blood flow (CBF) [6, 11, 23–25]. However, the effects of egg-protein hydrolysates on CBF have never been studied before. Additionally, the long-term maintenance of these cognitive performance benefits and their extension to other cognitive domains remain to be established. Therefore, the primary objective of this double-blind, randomized, placebo-controlled parallel study was to investigate long-term (36 weeks) effects of an NWT-03 intervention on cognitive performance and CBF, as quantified by the non-invasive magnetic resonance imaging (MRI) perfusion method Arterial Spin Labeling (ASL). Furthermore, we investigated effects on an additional cognitive domain, namely memory, which was assessed using the Cambridge Neuropsychological Test Battery (CANTAB). The intervention specifically targeted older adults experiencing elevated SCF, as they may benefit most from intervention strategies.

Materials and methods

Study participants

Forty-four older men and women aged between 60 and 75 with elevated SCF were recruited using online advertisements, posters in public buildings within Maastricht, and among participants who had taken part in prior studies. Interested candidates were invited for a screening visit to the university if they indicated that they had a BMI between 25 and 35 kg/m2 (overweight or obese), were right-handed, did not have any chronic medical conditions such as diabetes, hypertension, and active cardiovascular disease (CVD), and noticed that they were experiencing symptoms of cognitive decline. Anthropometrics, blood pressure, and fasting blood samples were taken during the screening visit. We utilized the Cognitive Failure Questionnaire (CFQ) [1, 26] to assess the presence of elevated SCF. This 25-item questionnaire evaluates the frequency of everyday cognitive errors based on a score of 1 (very often) to 5 (never). A cut-off value of ≥ 40 was used to define elevated SCF, which corresponds to approximately 23% of the older population [26]. In addition to the foregoing criteria, included participants needed to have a fasting plasma glucose < 7.0 mmol/L, serum total cholesterol < 8 mmol/L, serum triacylglycerol < 4.5 mmol/L, systolic blood pressure < 160 mmHg, diastolic blood pressure < 100 mmHg and a stable body weight. They also had to be willing to give up being a blood donor 8 weeks before and during the study, and 4 weeks after completion. Based on a questionnaire, they also needed to indicate that they did not possess any contraindications for an MRI scan. All study participants provided written informed consent before the start of the screening visit, and the study protocol was approved by the Medical Ethical Review Committee of the Maastricht University Hospital and Maastricht University (METC azM/UM) (NL75618.068.20) and registered at ClinicalTrials.gov in January 2021 as NCT04831203. This study has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments and was conducted from May 2021 until October 2022.

Study design

A 36-week double-blind, randomized, controlled parallel study was performed. The randomization was performed by an independent researcher using WinPepi Etcetera software, stratified for sex. The sachets were packaged in numbered boxes, aligning with a randomization process of which the investigators were unaware. These boxes were then dispensed by M.S.A. All study outcomes were performed at two baseline test days and identical follow-up visits. These measurements included anthropometrics (height, weight, body mass index [BMI], waist and hip circumferences, and skinfold measurements to determine body fat percentage [27]), cognitive performance (CANTAB) and brain vascular function (CBF). At weeks 9, 18, and 27, the participants revisited the university to obtain additional supplies and to return the empty sachets in order to check compliance. Moreover, food frequency questionnaires (FFQ) were filled out during baseline and follow-up visits to evaluate dietary intake during the previous 4 weeks [28]. They were instructed not to perform any strenuous physical exercise or consume alcoholic beverages 48 h before the test days, and to fast for 12 h before blood sampling. Moreover, to standardize measurements, participants were asked to come to the university by public transport or car instead of walking or biking. All measurements were performed by the same investigator (M.S.A.), at the same time of day, and at the same location (Metabolic Research Unit [MRUM] and the Scannexus research facilities in Maastricht). Finally, study participants were requested to record in study diaries any protocol deviations or changes in their health status, medication use, and alcohol intake.

Study products

Participants either received 5.7 g of the egg-protein hydrolysate product (NWT-03; Newtricious R&D, ‘s-Hertogenbosch, The Netherlands) or 5.7 g of a maltodextrin placebo in dry powder sachets to mix with 200 mL of water and to consume every day in the morning before breakfast. In addition, the spray-dried egg-protein hydrolysate (NWT-03; Nizo Food Research, Ede, The Netherlands) contained citric acid, flavoring, acesulfame K, sucralose, and quinine HCL. The matching placebo consisted of maltodextrin from potato starch, flavoring, citric acid, cloudifier, tartaric acid, malic acid, acesulfame K, sucralose, caramel E150a, and quinine HCL. The products were similar in color and taste (lemon flavor) to ensure the double-blind research design and packaged in a box that was labeled according to Good Manufacturing Process (GMP) guidelines.

Cognitive performance

In line with our prior studies [6, 29], cognitive performance was assessed using the fully automated CANTAB software on a digital touchscreen tablet (iPad, 5th generation; Apple). Written and verbal instructions were provided by the investigator to familiarize the participants with the tablet before proceeding to the cognitive tasks. In addition, the software offered further guidance and practice trials to ensure their understanding and proficiency in using the tablet.

To investigate psychomotor speed, the reaction time task (RTI) was performed, and the resulting reaction time (ms) and movement time (ms) were evaluated as outcome parameters. The executive function domain was appraised using the multitasking task (MTT) with incongruency cost (ms), median reaction latency (ms), multitasking cost (ms), and total incorrect errors as the key outcomes. Furthermore, the spatial working memory (SWM) task additionally served to evaluate executive function by analyzing between errors, total errors, and strategy scores. Lastly, the memory domain was examined with a delayed matching to sample (DMS) and paired associates learning (PAL) task. The percentage of correctly answered trials for all delays specified DMS results, whereas PAL was evaluated based on total errors and the first attempt memory score. A more detailed description of these tests has previously been provided [6].

Brain vascular function

MRI with ASL scans were performed on a Siemens 3.0 Tesla Magnetom Prisma Fit scanner with a 64-channel head coil. Detailed information regarding the acquisition and processing of MRI data has formerly been published [6, 29]. In short, participants remained in the supine position for an approximately 20-min acclimatization period during which an MPRAGE (T1 image) structural scan was acquired, and a labeling plane was situated based on an angiogram perpendicular to the vertebral and carotid arteries. Afterwards, pseudo-continuous arterial spin labeling (pCASL) with spin echo readouts and background suppressed segmented 3-D gradients were performed. Over the course of the 9-min sequence, parameters included a TR 4050 (repetition time), TE 13.6 ms (echo time), GRAPPA 2, labelling duration 1750 ms, post-labelling delay 2000 ms, and ten label-control repetitions.

Motion correction was automatically performed on the Siemens scanner. To perform brain extraction and tissue segmentation for the anatomical MPRAGE image, Volbrain [30] was used. Quantitative CBF images were estimated from the ASL data using FSL software (Version 6.0) [31], and perfusion-weighted images were generated by pairwise subtraction of label and control images on the pCASL data. Based on the recommendations of the ASL White Paper [32], the BASIL tool (v 4.0.15) [33] quantified perfusion-weighted images. Using boundary-based registration to the brain extracted MPRAGE image by the FLIRT routine [34], the calibrated ASL images with absolute CBF values were co-registered. Gray matter, global brain, and cortical and subcortical CBF values were also determined using the MPRAGE scan. Subsequently, voxel-wise comparisons [35] were conducted by first registering the absolute CBF values to MNI (2 mm) space using a nonlinear algorithm (FNIRT). Due to a high signal-to-noise ratio (SNR), smoothing was not performed and nonparametric permutation testing with a threshold-free cluster enhancement within FSL was used to determine significantly different clusters. These clusters were determined from applying an unpaired t-task with a single-group a paired difference (FMRIB’s Local Analysis of Mixed Effects stage 1 (FLAME) [36]), voxel connectivity of 26, and a z-threshold of 2.3 (p value < 0.05). Based on the smoothness estimates, family-wise corrections for multiple comparisons were performed. The Harvard–Oxford subcortical structural atlas and Atlasquery function were used to determine the average probability of the cluster locations.

Brain-derived neurotrophic factor

At baseline and follow-up visits, fasting serum samples were collected using venipuncture on the forearm. Samples were centrifuged at 1300 × g for 10 min at 21 °C after clotting for approximately 60 min, aliquoted, frozen in liquid nitrogen, and stored at −80 °C. At the end of the study, all samples were analyzed for brain-derived neurotrophic factor (BDNF) concentrations by an enzyme-linked immunosorbent assay (Duo Kit ELISA, R&D Systems, Minneapolis, USA) according to manufacturer’s instructions. The results are reported as the sum of precursor BDNF and mature BDNF because the assay did not differentiate between them.

Statistical analyses

Cognitive performance and CBF were the primary study outcomes for this NWT-03 intervention. Power calculations were conducted for an analysis of covariance (ANCOVA) with baseline measures of the outcomes as a covariate. It was calculated that 18 participants per group were needed to detect clinically relevant changes of at least 5% in reaction latency within the executive function domain (MTT task). This power calculation was based on our prior trial using a between-subject variability of 10%, correlation coefficient of 0.75 [29], > 80% power, and two-sided alpha of 0.05. Moreover, a sample size of 18 participants per group was also sufficient to reach a power >80% to detect changes in CBF of at least 10%, using a between-subject variability of 18%, correlation coefficient of 0.68 [37–39], and two-sided alpha of 0.05.

Using the Shapiro–Wilk test, all variables were normally distributed. A one-way ANCOVA, using the baseline measurements of the outcome variables as covariates and intervention as a fixed factor was conducted to determine differences in responses between intervention and placebo groups. In preliminary analyses, we incorporated age as a potential effect-modifier into the ANCOVA model. However, this factor did not affect the outcomes and was, therefore, omitted from the final model. Furthermore, post-hoc analyses using a sex × intervention interaction as a fixed factor were also performed to test for differential effects between men and women. If the interaction was significant, then we separated the men and women and reran the analysis. If it was not significant, then we removed the interaction term from the final model. All statistical analyses were performed using SPSS (IBM Corp., IBM SPSS Statistics, V27, Armonk, NY, USA) and differences were deemed statistically significant using two-tailed tests at p ≤ 0.05.

Results

Study participants

A Consolidated Standards of Reporting Trials (CONSORT) flow diagram is shown in Fig. 1. Forty-four eligible men (n = 26) and women (n = 18) were randomized into the intervention or placebo groups. The mean age of the participants was 69 ± 4 years, and their average BMI was 28.1 ± 2.6 kg/m2 (Table 1). Two people allocated to the intervention dropped out for personal reasons or because they disliked the taste of the product. An additional participant allocated to the placebo group dropped out due to starting high blood pressure medication. Finally, a fatal serious adverse event occurred in one participant who was consuming the placebo, which was approved by the METC azM/UM as unrelated to the ongoing investigation. Twenty participants in the intervention (n = 9 women, n = 11 men) and twenty participants in the placebo group completed the placebo (n = 7 women, n = 13 men) completed the study and were included in the analyses. After experiencing claustrophobia on the follow-up test day, one participant had missing CBF data. Additionally, one person was excluded from the BDNF analysis due to a missing value at baseline. No further serious adverse events or protocol deviations were reported in the study diaries and the study product was well tolerated. Compliance based on empty returned sachets was excellent (median: 99%; range: 87–103%). Anthropometrics including body weight, BMI, and body fat percentages derived from skinfold measurements, waist and hip circumferences, and waist-hip (W–H) ratio can be found in Table 2. Overall, anthropometrics parameters, as well as nutrient and energy consumption based on the FFQ, did not change in intervention and placebo groups from baseline to follow-up (Online Resource 1). No intervention effects were observed, and effects did not depend on sex.Fig. 1 Illustrates a Consolidated Standards of Reporting Trials (CONSORT) flow diagram. A total of forty-four eligible men and women were randomized into intervention or placebo groups. A total of 40 participants completed the study and were included in the statistical analysis. One participant was excluded from the MRI analysis due to experiencing claustrophobia on the follow-up test day. Another participant was excluded from the BDNF analysis due to a missing value at baseline

Table 1 Screening characteristics of overweight or obese older men and women with elevated SCF who completed the study (n = 40)

	All (n = 40)	Men (n = 23)	Women (n = 17)	
Age (years)	69 ± 4	69 ± 4	68 ± 4	
Height (cm)	172 ± 9	177 ± 7	165 ± 7	
Weight (kg)	84.0 ± 9.7	86.7 ± 8.1	79.0 ± 10.2	
BMI (kg/m2)	28.1 ± 2.6	27.7 ± 2.2	28.8 ± 3.1	
CFQ, 0–100	48 ± 8	47 ± 7	50 ± 9	
Systolic blood pressure (mmHg)	130 ± 12	131 ± 12	128 ± 13	
Diastolic blood pressure (mmHg)	80 ± 8	81 ± 8	78 ± 10	
Cholesterol (mmol/L)	5.9 ± 0.8	5.9 ± 0.9	6.1 ± 0.8	
Triacylglycerol (mmol/L)	1.6 ± 1.0	1.5 ± 0.6	1.6 ± 1.4	
Glucose (mmol/L)	5.6 ± 0.9	5.8 ± 0.5	5.3 ± 1.3	
Values are means ± SDs

BMI body mass index, CFQ Cognitive Failure Questionnaire, SCF Subjective Cognitive Failures

Table 2 Anthropometrics at baseline and follow-up after a protein hydrolysate intervention versus a placebo group in a double-blind randomized controlled trial in adults with  elevated SCF

	Intervention (n = 20)	Placebo (n = 20)	p valuea	
Baseline	Follow-up	Mean difference	Baseline	Follow-up	Mean difference	Intervention effect [95% CI]	Sex × intervention	Intervention	
Height (m)	172 ± 10	172 ± 10	0 ± 0	173 ± 8	173 ± 8	0 ± 0	0 [0, 0]	0.12	0.75	
Weight (kg)	82.9 ± 10.4	83.3 ± 9.9	0.4 ± 1.8	85.1 ± 9.4	84.9 ± 10.5	−0.1 ± 2.2	0.5 [−0.8, 1.9]	0.58	0.36	
BMI (kg/m2)	28.0 ± 2.8	28.2 ± 2.7	0.2 ± 0.6	28.3 ± 2.8	28.3 ± 3.4	0.0 ± 0.8	0.2 [−0.2, 0.6]	0.64	0.32	
Body fat (%)	33 ± 7	34 ± 7	0 ± 2	34 ± 7	34 ± 7	0 ± 1	0 [−1, 1]	0.43	0.71	
WC (cm)	99.8 ± 8.4	99.9 ± 8.4	0.0 ± 0.5	100.4 ± 8.3	100.4 ± 8.4	0.1 ± 0.6	0.0 [−0.4, 0.3]	0.22	0.79	
HC (cm)	107 ± 6	107 ± 6	0 ± 0	108 ± 7	108 ± 7	0 ± 1	0 [0, 0]	0.60	0.99	
W–H ratio	0.93 ± 0.07	0.93 ± 0.07	0.00 ± 0.01	0.93 ± 0.07	0.93 ± 0.07	0.00 ± 0.00	0.00 [0.00, 0.00]	0.92	0.63	
Values are means ± SDs

HC hip circumference, SCF Subjective Cognitive Failures, WC waist circumference, W–H ratio waist-to-hip ratio

aAn ANCOVA with baseline anthropometric values as a covariate and sex, intervention, and a sex × intervention interaction as fixed factors was first conducted. When the interaction term did not reach statistical significance, it was removed from the final model to estimate intervention effects. Intervention effects [95% CI] are reported after adjustment for baseline and sex

Cognitive performance

The outcomes of cognitive tests after the egg-protein hydrolysate (NWT-03) intervention compared to those after the placebo product are shown in Table 3. Overall, there were no significant intervention effects for any of the performed tasks encompassing the attention and psychomotor speed, executive function, and memory domains. However, a significant sex × intervention interaction effect was identified for the SWM executive function task. Additionally, the interaction for the MTT, the other executive function task, nearly reached statistical significance (p = 0.05). Specifically, more pronounced beneficial effects were observed in women as compared to men for the amount of between errors (p = 0.03) and total errors (p = 0.03) in the SWM task, and the reaction latency (p = 0.05) for the MTT task. Subsequently, analyses were repeated for men and women separately. A significant reduction of 9 (95% CI: −14 to −3; p < 0.001) for between errors and reduction of 9 (95% CI: −15 to −3; p < 0.001) for total errors on the SWM were observed in women, but not in men (Fig. 2). Likewise, women demonstrated a reduction of 74 ms in reaction latency on the MTT (95% CI: −134 to −15; p = 0.02), but this effect was not observed in men. Effects for the attention and psychomotor speed, and memory tasks did, however, not differ between men and women. Table 3 Outcomes of psychomotor speed and executive function cognitive tasks after a protein hydrolysate intervention versus a placebo group in adouble-blind randomized controlled trial in adults with elevated SCF

	Intervention (n = 20)	Placebo (n = 20)	p valuea	
Baseline	Follow-up	Mean difference	Baseline	Follow-up	Mean difference	Intervention effect [95% CI]	Sex x intervention	Intervention	
Psychomotor speed	
RTI movement time (ms)	309 ± 69	303 ± 81	−6 ± 48	307 ± 87	298 ± 71	−9 ± 51	−17 [−47, 14]	0.90	0.27	
RTI reaction time (ms)	389 ± 36	399 ± 41	10 ± 23	386 ± 37	384 ± 38	−3 ± 28	−2 [−19, 14]	0.84	0.76	
Executive function	
MTT incongruency cost (ms)	137 ± 80	131 ± 61	−5 ± 58	120 ± 57	107 ± 66	−13 ± 88	10 [−27, 48]	0.64	0.58	
MTT multitasking cost (ms)	256 ± 128	201 ± 94	−55 ± 125	287 ± 180	255 ± 161	−32 ± 174	9 [−67, 86]	0.98	0.80	
MTT mean latency (ms)	764 ± 121	741 ± 104	−24 ± 71	781 ± 115	775 ± 112	−6 ± 69		0.05		
MTT (total errors)	9 ± 12	9 ± 11	0 ± 11	12 ± 14	11 ± 15	−1 ± 13	−5 [−12, 2]	0.92	0.13	
SWM (between errors)	14 ± 10	14 ± 10	0 ± 8	15 ± 10	17 ± 9	2 ± 7		0.03		
SWM (strategy score)	8 ± 3	8 ± 3	0 ± 2	8 ± 3	9 ± 2	1 ± 3	0 [−1, 2]	0.18	0.58	
SWM (total errors)	14 ± 10	15 ± 10	0 ± 8	15 ± 10	17 ± 10	2 ± 8		0.03		
Memory	
DMS (% correct)	79 ± 13	85 ± 14	5 ± 19	80 ± 12	84 ± 9	4 ± 15	−2 [−11, 6]	0.91	0.57	
PAL (1st attempt memory score)	9 ± 3	10 ± 4	1 ± 3	11 ± 3	12 ± 3	1 ± 3	0 [−2, 2]	0.49	0.73	
PAL (total errors)	26 ± 14	23 ± 15	−3 ± 11	21 ± 13	18 ± 11	−4 ± 11	−5 [−6, 7]	0.88	0.88	
Values are means ± SDs

DMS delayed matching to sample, MTT multitasking task, PAL paired associates learning, RTI reaction time task, SCF Subjective Cognitive Failures, SWM spatial working memory

aAn ANCOVA with baseline cognitive performance values as a covariate and sex, intervention, and a sex × intervention interaction as fixed factors was first conducted. When the interaction term did not reach statistical significance, it was removed from the final model to estimate intervention effects. Intervention effects [95% CI] are reported after adjustment for baseline and sex

Fig. 2 Changes in the cognitive performance SWM and MTT tasks for the whole group, and women and men separately after a protein hydrolysate intervention versus a placebo group in a double-blind randomized controlled trial in adults with elevated SCF. Values are means ± SEM. MTT, multitasking task; SCF, Subjective Cognitive Failures; SWM, spatial working memory. Tasks from baseline to follow-up in the placebo and intervention groups. a SWM, between errors b SWM, total errors c MTT reaction latency, ms

Brain vascular function

As compared to the placebo, the NWT-03 intervention did not affect the whole-brain (p = 0.98), gray matter (p = 0.83), cortical (p = 0.99), and subcortical CBF (p = 0.92) (Table 4). Moreover, no significant sex × intervention interactions were observed, indicating that these results did not differ between men and women. Voxel-wise comparisons also did not reveal brain clusters that were differently affected between intervention and placebo groups. These comparisons were repeated for men and women separately, but study results did not differ. Visual representations of the average perfusion-weighted images at baseline and at follow-up for the intervention and placebo groups are depicted in Fig. 3. Table 4 Outcomes of cerebral blood flow (CBF, ml/100 g brain tissue/min)a and brain-derived neurotrophic factor (BDNF, pg/mL)b after a protein hydrolysate intervention versus a placebo group in a double-blind randomized controlled trial in adults with elevated SCF

	Intervention	Placebo	p valuea	
Baseline	Follow-up	Mean difference	Baseline	Follow-up	Mean difference	Intervention effect [95% CI]	Sex × intervention	Intervention	
CBF (mL/100 g/min)	
Whole-brain	35.2 ± 8.1	35.0 ± 8.7	−0.3 ± 4.3	38.6 ± 7.2	37.7 ± 6.3	−0.9 ± 5.2	−0.0 [−3.1, 3.0]	0.39	0.98	
Gray matter	41.6 ± 10.2	40.8 ± 10.0	−0.7 ± 5.4	45.1 ± 8.3	43.9 ± 7.4	−1.2 ± 6.2	−0.7 [−4.4, 3.0]	0.39	0.83	
Cortical	45.5 ± 11.0	45.0 ± 11.2	−0.5 ± 5.5	49.3 ± 8.6	48.0 ± 8.0	−1.3 ± 6.9	0.0 [−4.0, 4.0]	0.31	0.99	
Subcortical	27.0 ± 8.4	26.4 ± 8.0	−0.6 ± 3.6	29.9 ± 9.1	28.9 ± 8.5	−1.0 ± 4.0	−0.1 [−2.5, 2.3]	0.38	0.92	
BDNF (pg/mL)	
Serum concentrations	20,620 ± 6283	17,501 ± 6920	−3119 ± 10,046	21,896 ± 6471	19,754 ± 8717	−1,047 ± 13,132	−3272 [−9312, 2768]	0.62	0.31	
SCF Subjective Cognitive Failures

a [Values are means ± SDs; n = 39 (intervention = 19; placebo = 20)]

b [Values are means ± SDs; n = 39 (intervention = 20; placebo = 19)]

cAn ANCOVA with baseline CBF and BDNF values as a covariate and sex, intervention, and a sex × intervention interaction as fixed factors was first conducted. When the interaction term did not reach statistical significance, it was removed from the final model to estimate intervention effects. Intervention effects [95% CI] are reported after adjustment for baseline and sex

Fig. 3 Pseudo-continuous arterial spin labeling (ASL) perfusion-weighted images which were acquired at the Scannexus research facility for a protein hydrolysate intervention versus a placebo group in a double-blind randomized controlled trial in adults with elevated SCF. The cerebral blood flow (CBF) is shown by the color bar in mL/70 g tissue/min. a Mean CBF map from the intervention (n = 19) at baseline b Mean CBF map from the intervention (n = 19) at follow-up c Mean CBF map from the placebo (n = 20) at baseline d Mean CBF map from the placebo (n = 20) at follow-up. SCF, subjective cognitive failures

Brain-derived neurotrophic factor

Changes in serum BDNF concentrations did not significantly differ between the intervention and placebo groups (p = 0.31). Additionally, effects did not depend on sex (p = 0.62; Table 4).

Discussion

This double-blind, randomized, controlled parallel study has valuated the effects of the long-term consumption of the egg-protein hydrolysate NWT-03 on cognitive performance and brain vascular function in overweight or obese older adults with elevated SCF. Cognitive impairments are commonly associated with a higher risk of developing dementia [3] and frequently exhibits additional underlying metabolic risk factors, such as insulin resistance [40, 41] and impaired vascular function [42, 43]. Overall, no effects of NWT-03 were observed on cognitive performance tasks. However, for both executive function tasks (SWM and MTT), we observed more beneficial effects of the intervention in women, but not for men. Moreover, regional and voxel-wise CBF did not change, and these brain vascular function outcomes also did not differ between men and women. Additionally, no differences in serum BDNF concentrations, anthropometric measurements, and energy and nutrient intakes were found that could explain the observed changes on executive function, as these variables were comparable at baseline and did not change during the study.

Cognitive performance on tasks encompassing the attention and psychomotor speed, executive function, and memory domains did not change when all participants were analyzed from baseline to follow-up. However, after a significant sex × intervention interaction was observed, analyses were repeated for men and women separately. Improvements were observed in women for two independent executive functioning tasks. More specifically, in women, we observed a reduction in reaction latency on the MTT, along with fewer total errors and fewer between-task errors on the SWM. Improvements on the MTT task suggest that participants can multitask better by ignoring irrelevant information, while improvements in the SWM task suggest better working memory and ability to use a strategy to manipulate visuospatial information [44]. For the SWM task, the placebo group observed a worsening in cognitive performance, which could also be interpreted as NWT-03 providing a protective effect against deterioration. However, we would not expect that such a deterioration could already occur over 36-weeks, and this worsening would have also been expected to be observed in the MTT task assessing the same cognitive domain. These findings are in line with observed improvements on executive function in our prior short-term intervention study involving the consumption of a comparable amount of NWT-03 (5.0 g vs. 5.7 g in the current study) for 4 weeks [17]. In particular, a reduction in response time during the anti-cue paradigm was found, an executive function task which is analogous to the MTT and SWM tasks provided by CANTAB [18]. Therefore, our findings suggest that the short-term effects that we previously observed in adults with metabolic syndrome are maintained in the long-term for a higher-risk population of women with elevated SCF. People with subjective cognitive complaints are at a greater risk for developing Mild Cognitive Impairment (MCI) [45], where evidence already supports that 16% of MCI patients can reverse their diagnosis [46], also through non-pharmacological means [47]. This evidence highlights the potential clinical relevance of our study.

An important question remains as to why improvements on executive function were limited to women, rather than being observed in both sexes, as was noted in our previous study involving participants with metabolic syndrome [17]. Furthermore, we need to address the lack of impact on the attention and psychomotor speed and memory domains. Based on the slightly higher SCF experienced in women (mean = 50) compared to men (mean = 47), it may be hypothesized that the women may have had more room to benefit from a dietary intervention impacting executive function at this stage in their life. Therefore, a population of older men and women with elevated SCF cannot be directly compared to a population with younger individuals and metabolic syndrome. However, more research is needed to confirm or refute these speculations. In support, two soy studies, specifically targeting older women, have already demonstrated improvements on executive function [13, 14]. Similarly, Mohajeri and colleagues conducted an egg-protein hydrolysate intervention exclusively in middle-aged women, which also showed improvements on executive function [7]. These studies exemplify that women can benefit from dietary protein interventions, although it is unclear why in studies using a casein peptide [16], a peanut intervention [11], a multi-nutrient whey protein supplementation [12], and a high protein diet [15], results did not differ between women and men. However, apart from the egg-protein hydrolysate [7] and casein-derived peptide [16] studies, the other interventions contained non-protein components that do not allow us to completely attribute these beneficial effects to dietary proteins. Therefore, more RCTs on dietary proteins including both men and women which are adequately powered to detect sex differences are needed. Although underlying mechanisms are not entirely clear, it could be speculated that physiological differences between older men and women with elevated SCF play a role. In fact, it has been established that a combination of factors including hormonal changes due to menopause that also impact metabolism [48] cause faster cognitive decline in women compared to men [49]. This was particularly observed for executive function, but not for memory, and may be related to the fact that a decline on executive function is one of the first symptoms of dementia in women [50]. Furthermore, one observational study found significant associations between better cognitive function with plant and total protein intake in women, but not in men [51]. In a case–control study of patients with dementia and healthy controls, lower cognitive function in dementia patients was also associated with lower protein intake, but only in women [52].

NWT-03 has been shown to potentially improve peripheral vascular function [19] and cardiometabolic risk markers [20]. However, it still remained to be investigated whether these beneficial peripheral effects extend to the brain, as impaired brain vascular function is considered an important mechanism preceding the development of an impaired cognitive performance [21, 22]. Notably, CBF was not affected in this study, which indicates that other mechanisms may be involved for the cognitive performance benefits observed in women. Both a voxel-wise and regional approach to evaluate differences in CBF were used, the prior examining differences in the amount of CBF by comparing brain images pixel by pixel, whereas the latter uses the volume of the entire brain or specific brain regions based on an atlas [53]. Unlike previous dietary protein intervention studies that employed indirect techniques such as transcranial doppler ultrasound or near-infrared spectroscopy [11, 23, 25, 54], the utilization of an ASL voxel-wise approach allows for the detection of local differences that may have been previously overlooked [55]. Additionally, it can be pointed out that, although other studies in our lab have evaluated regional and voxel-wise CBF in older, overweight or obese populations using ASL [6, 56], the current study demonstrated comparatively lower baseline CBF values. This difference suggests that the participants’ brain vascular function, related to their elevated SCF status, may have declined below a threshold that makes it more challenging to influence CBF through protein hydrolysate interventions. Although CBF was not impacted, it is still possible that the small peptide components of NWT-03 crossed the blood–brain barrier (BBB) [57] and directly bound to receptors that modulate the release of neurotransmitters in specific brain regions [58], thereby improving executive function in women, without impacting brain vascular function. This possibility is supported by previous research on animal models that gene expression patterns and sex-specific genes can influence BBB permeability [59–61], resulting in potential differences in men and women’s peptide uptake. Alternatively, we can speculate that there may be a direct link between peripheral vascular function and cognitive performance, which may elucidate the observed effects on cognitive performance, without mediating effects of CBF. This could be through mechanisms impacting oxidative stress and inflammation, BBB integrity, neurotransmitter balance and brain insulin uptake [62–65]. Alternatively, changes in BDNF concentrations have been shown to improve cognition [66] through dietary interventions [67] by promoting synaptic plasticity and neurogenesis. However, no overall intervention effects were observed and, therefore, we can conclude that these improvements on executive function in women were not impacted by changes in serum BDNF. This is consistent with the findings observed in the 4-week study on NWT-03 [17], but we cannot eliminate the possibility that BDNF concentrations changed in the brain.

This double-blind, randomized, placebo-controlled parallel study had several strengths and weaknesses. First, the primary study outcomes were assessed using validated, reproducible methods to evaluate changes in brain vascular function [68, 69] and cognitive performance [44, 70–72]. In fact, the use of MRI with ASL [68] allows for a highly reproducible method of quantification of CBF [69]. To the best of our knowledge, this was also the first protein hydrolysate intervention to focus on a well-defined study population involving older adults with elevated SCF using a validated questionnaire [1, 26]. Finally, no study-related serious adverse events or protocol deviations were reported in the study diaries and the study product was well tolerated. One limitation of our study is its focus on a specific, homogenous target population, which may limit the generalizability of our findings. Additionally, while our study offers insights into cognitive performance outcomes and regional CBF differences, it underscores the importance of including sex as a consideration in the power calculations of future studies to further elucidate these effects. Finally, we do not have conclusive evidence of COVID-19 infections among our study participants throughout the duration of the study, and the randomization process in our study design was intended to mitigate any potential imbalance caused by undetected COVID-19 cases. However, we acknowledge that we cannot completely rule out the possibility that undetected or previous COVID-19 infections modified intervention effects observed following long-term consumption of NWT-03.

Conclusion

Our data indicate that daily intake of 5.7 g NWT-03 for 36 weeks did not affect overall cognitive performance in an older population consisting of adults with elevated SCF, but evidence was provided for beneficial effects on parameters reflecting executive function in postmenopausal women as compared to men. There were no changes in the psychomotor speed or memory domains. In our previous 4-week NWT-03 study, changes on executive function were observed [17], which aligns with the current findings. Furthermore, this study expands on these results by demonstrating the long-term maintenance of the observed beneficial effects. However, no beneficial effects were found in regional and voxel-wise CBF using ASL, and the potentially differential results between men and women to an egg-protein hydrolysate intervention also still remains to be elucidated.

Supplementary Information

Below is the link to the electronic supplementary material.Supplementary file1 (XLSX 15 KB)

Acknowledgements

The authors would like to thank all volunteers for participating, K. M. R. Nijssen and J. Kleinloog for their practical support, and E. Kornips for the biochemical analyses.

Author contributions

M.S.A.: conducted the research, analyzed the data, performed the statistical analyses, interpreted the data, and wrote the manuscript; R.P.M. and J.P.: designed the study, interpreted the data, and wrote the manuscript; P.J.J.: designed the study, interpreted the data, had overall responsibility for the study, and wrote the manuscript.

Funding

This study was granted by Life Sciences Health—TKI (Health Holland), The Hague, The Netherlands. Newtricious R&D (‘s-Hertogenbosch, The Netherlands) provided the study products.

Data availability

The datasets produced and/or examined in the present study can be obtained upon a reasonable request from the corresponding author (P.J.J.).

Declarations

Conflict of interest

The authors have no conflicts of interest to declare.

Ethical standards

All study participants provided written informed consent before the start of the screening visit and the study protocol was approved by the Medical Ethical Review Committee of the Maastricht University Hospital and Maastricht University (METC azM/UM) (NL75618.068.20) and registered at ClinicalTrials.gov in January 2021 as NCT04831203. This study has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

Clinical trials registration: the study was registered at ClinicalTrials.gov in January 2021 as NCT04831203.

Sources of support: This study was granted by Life Sciences Health—TKI (Health Holland), The Hague, The Netherlands in combination with support from Newtricious R&D (‘s-Hertogenbosch, The Netherlands), which provided the study products.
==== Refs
References

1. Broadbent DE Cooper PF FizGerald P The Cognitive Failures Questionnaire (CFQ) and its correlates Br J Clin Psychol 1982 21 1 16 10.1111/j.2044-8260.1982.tb01421.x 7126941
Broadbent DE, Cooper PF, FizGerald P et al (1982) The Cognitive Failures Questionnaire (CFQ) and its correlates. Br J Clin Psychol 21:1–16. 10.1111/j.2044-8260.1982.tb01421.x7126941 10.1111/j.2044-8260.1982.tb01421.x
2. Sutin AR Aschwanden D Stephan Y Five factor model personality traits and subjective cognitive failures Pers Individ Dif 2020 155 109741 10.1016/j.paid.2019.109741 32863506
Sutin AR, Aschwanden D, Stephan Y et al (2020) Five factor model personality traits and subjective cognitive failures. Pers Individ Dif 155:109741. 10.1016/j.paid.2019.10974132863506 10.1016/j.paid.2019.109741
3. van Norden AGW Fick WF de Laat KF Subjective cognitive failures and hippocampal volume in elderly with white matter lesions Neurology 2008 71 1152 1159 10.1212/01.wnl.0000327564.44819.49 18838662
van Norden AGW, Fick WF, de Laat KF et al (2008) Subjective cognitive failures and hippocampal volume in elderly with white matter lesions. Neurology 71:1152–1159. 10.1212/01.wnl.0000327564.44819.4918838662 10.1212/01.wnl.0000327564.44819.49
4. Scarmeas N Anastasiou CA Yannakoulia M Nutrition and prevention of cognitive impairment Lancet Neurol 2018 17 1006 1015 10.1016/S1474-4422(18)30338-7 30244829
Scarmeas N, Anastasiou CA, Yannakoulia M (2018) Nutrition and prevention of cognitive impairment. Lancet Neurol 17:1006–1015. 10.1016/S1474-4422(18)30338-730244829 10.1016/S1474-4422(18)30338-7
5. Duffy R Wiseman H File SE Improved cognitive function in postmenopausal women after 12 weeks of consumption of a soya extract containing isoflavones Pharmacol Biochem Behav 2003 75 721 729 10.1016/s0091-3057(03)00116-3 12895690
Duffy R, Wiseman H, File SE (2003) Improved cognitive function in postmenopausal women after 12 weeks of consumption of a soya extract containing isoflavones. Pharmacol Biochem Behav 75:721–729. 10.1016/s0091-3057(03)00116-312895690 10.1016/s0091-3057(03)00116-3
6. Kleinloog JPD Tischmann L Mensink RP Longer-term soy nut consumption improves cerebral blood flow and psychomotor speed: results of a randomized, controlled crossover trial in older men and women Am J Clin Nutr 2021 114 2097 2106 10.1093/ajcn/nqab289 34510189
Kleinloog JPD, Tischmann L, Mensink RP et al (2021) Longer-term soy nut consumption improves cerebral blood flow and psychomotor speed: results of a randomized, controlled crossover trial in older men and women. Am J Clin Nutr 114:2097–2106. 10.1093/ajcn/nqab28934510189 10.1093/ajcn/nqab289
7. Mohajeri MH Wittwer J Vargas K Chronic treatment with a tryptophan-rich protein hydrolysate improves emotional processing, mental energy levels and reaction time in middle-aged women Br J Nutr 2015 113 350 365 10.1017/S0007114514003754 25572038
Mohajeri MH, Wittwer J, Vargas K et al (2015) Chronic treatment with a tryptophan-rich protein hydrolysate improves emotional processing, mental energy levels and reaction time in middle-aged women. Br J Nutr 113:350–365. 10.1017/S000711451400375425572038 10.1017/S0007114514003754
8. Rondanelli M Cereda E Klersy C Improving rehabilitation in sarcopenia: a randomized-controlled trial utilizing a muscle-targeted food for special medical purposes J Cachexia Sarcopenia Muscle 2020 11 1535 1547 10.1002/jcsm.12532 32961041
Rondanelli M, Cereda E, Klersy C et al (2020) Improving rehabilitation in sarcopenia: a randomized-controlled trial utilizing a muscle-targeted food for special medical purposes. J Cachexia Sarcopenia Muscle 11:1535–1547. 10.1002/jcsm.1253232961041 10.1002/jcsm.12532
9. van der Zwaluw NL van de Rest O Tieland M The impact of protein supplementation on cognitive performance in frail elderly Eur J Nutr 2014 53 803 812 10.1007/s00394-013-0584-9 24045855
van der Zwaluw NL, van de Rest O, Tieland M et al (2014) The impact of protein supplementation on cognitive performance in frail elderly. Eur J Nutr 53:803–812. 10.1007/s00394-013-0584-924045855 10.1007/s00394-013-0584-9
10. Zajac IT Herreen D Bastiaans K The effect of whey and soy protein isolates on cognitive function in older australians with low vitamin B12: a randomised controlled crossover trial Nutrients 2018 11 19 10.3390/nu11010019 30577611
Zajac IT, Herreen D, Bastiaans K et al (2018) The effect of whey and soy protein isolates on cognitive function in older australians with low vitamin B12: a randomised controlled crossover trial. Nutrients 11:19. 10.3390/nu1101001930577611 10.3390/nu11010019
11. Barbour JA Howe PRC Buckley JD Cerebrovascular and cognitive benefits of high-oleic peanut consumption in healthy overweight middle-aged adults Nutr Neurosci 2017 20 555 562 10.1080/1028415X.2016.1204744 27386745
Barbour JA, Howe PRC, Buckley JD et al (2017) Cerebrovascular and cognitive benefits of high-oleic peanut consumption in healthy overweight middle-aged adults. Nutr Neurosci 20:555–562. 10.1080/1028415X.2016.120474427386745 10.1080/1028415X.2016.1204744
12. Bell KE Fang H Snijders T A multi-ingredient nutritional supplement in combination with resistance exercise and high-intensity interval training improves cognitive function and increases N-3 index in healthy older men: a randomized controlled trial Front Aging Neurosci 2019 11 107 10.3389/fnagi.2019.00107 31143111
Bell KE, Fang H, Snijders T et al (2019) A multi-ingredient nutritional supplement in combination with resistance exercise and high-intensity interval training improves cognitive function and increases N-3 index in healthy older men: a randomized controlled trial. Front Aging Neurosci 11:107. 10.3389/fnagi.2019.0010731143111 10.3389/fnagi.2019.00107
13. File SE Jarrett N Fluck E Eating soya improves human memory Psychopharmacology 2001 157 430 436 10.1007/s002130100845 11605103
File SE, Jarrett N, Fluck E et al (2001) Eating soya improves human memory. Psychopharmacology 157:430–436. 10.1007/s00213010084511605103 10.1007/s002130100845
14. File SE Hartley DE Elsabagh S Cognitive improvement after 6 weeks of soy supplements in postmenopausal women is limited to frontal lobe function Menopause 2005 12 193 201 10.1097/00042192-200512020-00014 15772567
File SE, Hartley DE, Elsabagh S et al (2005) Cognitive improvement after 6 weeks of soy supplements in postmenopausal women is limited to frontal lobe function. Menopause 12:193–201. 10.1097/00042192-200512020-0001415772567 10.1097/00042192-200512020-00014
15. Jakobsen LH Kondrup J Zellner M Effect of a high protein meat diet on muscle and cognitive functions: a randomised controlled dietary intervention trial in healthy men Clin Nutr 2011 30 303 311 10.1016/j.clnu.2010.12.010 21239090
Jakobsen LH, Kondrup J, Zellner M et al (2011) Effect of a high protein meat diet on muscle and cognitive functions: a randomised controlled dietary intervention trial in healthy men. Clin Nutr 30:303–311. 10.1016/j.clnu.2010.12.01021239090 10.1016/j.clnu.2010.12.010
16. Yuda N Tanaka M Yamauchi K Effect of the casein-derived peptide Met-Lys-Pro on cognitive function in community-dwelling adults without dementia: a randomized, double-blind, placebo-controlled trial Clin Interv Aging 2020 15 743 754 10.2147/CIA.S253116 32546992
Yuda N, Tanaka M, Yamauchi K et al (2020) Effect of the casein-derived peptide Met-Lys-Pro on cognitive function in community-dwelling adults without dementia: a randomized, double-blind, placebo-controlled trial. Clin Interv Aging 15:743–754. 10.2147/CIA.S25311632546992 10.2147/CIA.S253116
17. Gravesteijn E Adam JJ Mensink RP Effects of the egg protein hydrolysate NWT-03 on cognitive function in men and women with the metabolic syndrome: a randomized, double-blind, placebo-controlled study Nutr Neurosci 2022 26 1212 1221 10.1080/1028415X.2022.2144204 36373820
Gravesteijn E, Adam JJ, Mensink RP et al (2022) Effects of the egg protein hydrolysate NWT-03 on cognitive function in men and women with the metabolic syndrome: a randomized, double-blind, placebo-controlled study. Nutr Neurosci 26:1212–1221. 10.1080/1028415X.2022.214420436373820 10.1080/1028415X.2022.2144204
18. Adam JJ Jennings S Bovend’Eerdt TJH Switch hands! Mapping temporal dynamics of proactive manual control with anticues Acta Physiol (Oxf) 2015 161 137 144 10.1016/j.actpsy.2015.09.005
Adam JJ, Jennings S, Bovend’Eerdt TJH et al (2015) Switch hands! Mapping temporal dynamics of proactive manual control with anticues. Acta Physiol (Oxf) 161:137–144. 10.1016/j.actpsy.2015.09.00510.1016/j.actpsy.2015.09.005
19. Plat J Severins N Mensink RP Improvement of pulse wave velocity and metabolic cardiovascular risk parameters through egg protein hydrolysate intake: a randomized trial in overweight or obese subjects with impaired glucose tolerance or type 2 diabetes J Funct Foods 2019 52 418 423 10.1016/j.jff.2018.11.020
Plat J, Severins N, Mensink RP (2019) Improvement of pulse wave velocity and metabolic cardiovascular risk parameters through egg protein hydrolysate intake: a randomized trial in overweight or obese subjects with impaired glucose tolerance or type 2 diabetes. J Funct Foods 52:418–423. 10.1016/j.jff.2018.11.02010.1016/j.jff.2018.11.020
20. Plat J Severins N Morrison S Effects of NWT-03, an egg-protein hydrolysate, on blood pressure in normotensive, high-normotensive and mild-hypertensive men and women: a dose-finding study Br J Nutr 2017 117 942 950 10.1017/S0007114517000836 28485264
Plat J, Severins N, Morrison S et al (2017) Effects of NWT-03, an egg-protein hydrolysate, on blood pressure in normotensive, high-normotensive and mild-hypertensive men and women: a dose-finding study. Br J Nutr 117:942–950. 10.1017/S000711451700083628485264 10.1017/S0007114517000836
21. Marshall RS Lazar RM Pumps, aqueducts, and drought management: vascular physiology in vascular cognitive impairment Stroke 2011 42 221 226 10.1161/STROKEAHA.110.595645 21148438
Marshall RS, Lazar RM (2011) Pumps, aqueducts, and drought management: vascular physiology in vascular cognitive impairment. Stroke 42:221–226. 10.1161/STROKEAHA.110.59564521148438 10.1161/STROKEAHA.110.595645
22. Joris PJ Mensink RP Adam TC Cerebral blood flow measurements in adults: a review on the effects of dietary factors and exercise Nutrients 2018 10 530 10.3390/nu10050530 29693564
Joris PJ, Mensink RP, Adam TC et al (2018) Cerebral blood flow measurements in adults: a review on the effects of dietary factors and exercise. Nutrients 10:530. 10.3390/nu1005053029693564 10.3390/nu10050530
23. Ano Y Kita M Kobayashi K Effects of β-lactolin on regional cerebral blood flow within the dorsolateral prefrontal cortex during working memory task in healthy adults: a randomized controlled trial J Clin Med 2021 10 480 10.3390/jcm10030480 33525551
Ano Y, Kita M, Kobayashi K et al (2021) Effects of β-lactolin on regional cerebral blood flow within the dorsolateral prefrontal cortex during working memory task in healthy adults: a randomized controlled trial. J Clin Med 10:480. 10.3390/jcm1003048033525551 10.3390/jcm10030480
24. Akazawa N Hamasaki A Tanahashi K Lactotripeptide ingestion increases cerebral blood flow velocity in middle-aged and older adults Nutr Res 2018 53 61 66 10.1016/j.nutres.2018.03.009 29703414
Akazawa N, Hamasaki A, Tanahashi K et al (2018) Lactotripeptide ingestion increases cerebral blood flow velocity in middle-aged and older adults. Nutr Res 53:61–66. 10.1016/j.nutres.2018.03.00929703414 10.1016/j.nutres.2018.03.009
25. Ano Y Kobayashi K Hanyuda M β-lactolin increases cerebral blood flow in dorsolateral prefrontal cortex in healthy adults: a randomized controlled trial Aging (Albany NY) 2020 12 18660 18675 10.18632/aging.103951 32989176
Ano Y, Kobayashi K, Hanyuda M et al (2020) β-lactolin increases cerebral blood flow in dorsolateral prefrontal cortex in healthy adults: a randomized controlled trial. Aging (Albany NY) 12:18660–18675. 10.18632/aging.10395132989176 10.18632/aging.103951
26. Ponds R van Boxtel MPJ Jolles J De ‘Cognitive Failure Questionnaire’ als maat voor subjectief cognitief functioneren Tijdschrift voor neuropsychologie 2006 1 37 45
Ponds R, van Boxtel MPJ, Jolles J (2006) De ‘Cognitive Failure Questionnaire’ als maat voor subjectief cognitief functioneren. Tijdschrift voor neuropsychologie 1:37–45
27. Tischmann L Adam TC Mensink RP Longer-term soy nut consumption improves vascular function and cardiometabolic risk markers in older adults: results of a randomized, controlled cross-over trial Clin Nutr 2022 41 1052 1058 10.1016/j.clnu.2022.03.014 35395555
Tischmann L, Adam TC, Mensink RP et al (2022) Longer-term soy nut consumption improves vascular function and cardiometabolic risk markers in older adults: results of a randomized, controlled cross-over trial. Clin Nutr 41:1052–1058. 10.1016/j.clnu.2022.03.01435395555 10.1016/j.clnu.2022.03.014
28. RIVM. Dutch Food Composition Database NEVO online. Version 2021/7.0. December 2021. https://nevo-online.rivm.nl
29. Kleinloog JPD Mensink RP Ivanov D Aerobic exercise training improves cerebral blood flow and executive function: a randomized, controlled cross-over trial in sedentary older men Front Aging Neurosci 2019 11 333 10.3389/fnagi.2019.00333 31866855
Kleinloog JPD, Mensink RP, Ivanov D et al (2019) Aerobic exercise training improves cerebral blood flow and executive function: a randomized, controlled cross-over trial in sedentary older men. Front Aging Neurosci 11:333. 10.3389/fnagi.2019.0033331866855 10.3389/fnagi.2019.00333
30. Manjón JV Coupé P volBrain: an online MRI brain volumetry system Front Neuroinform 2016 10 30 10.3389/fninf.2016.00030 27512372
Manjón JV, Coupé P (2016) volBrain: an online MRI brain volumetry system. Front Neuroinform 10:30. 10.3389/fninf.2016.0003027512372 10.3389/fninf.2016.00030
31. Woolrich MW Jbabdi S Patenaude B Bayesian analysis of neuroimaging data in FSL NeuroImage 2009 45 S173 S186 10.1016/j.neuroimage.2008.10.055 19059349
Woolrich MW, Jbabdi S, Patenaude, B et al (2009) Bayesian analysis of neuroimaging data in FSL. NeuroImage 45:S173-S186. 10.1016/j.neuroimage.2008.10.05519059349 10.1016/j.neuroimage.2008.10.055
32. Alsop DC Detre JA Golay X Recommended implementation of arterial spin-labeled perfusion MRI for clinical applications: a consensus of the ISMRM perfusion study group and the European consortium for ASL in dementia Magn Reson Med 2015 73 102 116 10.1002/mrm.25197 24715426
Alsop DC, Detre JA, Golay X et al (2015) Recommended implementation of arterial spin-labeled perfusion MRI for clinical applications: a consensus of the ISMRM perfusion study group and the European consortium for ASL in dementia. Magn Reson Med 73:102–116. 10.1002/mrm.2519724715426 10.1002/mrm.25197
33. Chappell MA Groves AR Whitcher B Variational Bayesian inference for a nonlinear forward model IEEE Trans Signal Process 2009 57 223 236 10.1109/TSP.2008.2005752
Chappell MA, Groves AR, Whitcher B et al (2009) Variational Bayesian inference for a nonlinear forward model. IEEE Trans Signal Process 57:223–236. 10.1109/TSP.2008.200575210.1109/TSP.2008.2005752
34. Jenkinson M Bannister P Brady M Improved optimization for the robust and accurate linear registration and motion correction of brain images Neuroimage 2002 17 825 841 10.1006/nimg.2002.1132 12377157
Jenkinson M, Bannister P, Brady M et al (2002) Improved optimization for the robust and accurate linear registration and motion correction of brain images. Neuroimage 17:825–841. 10.1006/nimg.2002.113212377157 10.1006/nimg.2002.1132
35. Astrakas LG Argyropoulou MI Shifting from region of interest (ROI) to voxel-based analysis in human brain mapping Pediatr Radiol 2010 40 1857 1867 10.1007/s00247-010-1677-8 20464386
Astrakas LG, Argyropoulou MI (2010) Shifting from region of interest (ROI) to voxel-based analysis in human brain mapping. Pediatr Radiol 40:1857–1867. 10.1007/s00247-010-1677-820464386 10.1007/s00247-010-1677-8
36. Woolrich MW Behrens TEJ Beckmann CF Jenkinson M Smith SM Multilevel linear modelling for FMRI group analysis using Bayesian inference Neuroimage 2004 21 1732 1747 10.1016/j.neuroimage.2003.12.023 15050594
Woolrich MW, Behrens TEJ, Beckmann CF, Jenkinson M, Smith SM (2004) Multilevel linear modelling for FMRI group analysis using Bayesian inference. Neuroimage 21:1732–1747. 10.1016/j.neuroimage.2003.12.02315050594 10.1016/j.neuroimage.2003.12.023
37. Armitage P Berry G Matthews JNS Statistical methods in medical research 2013 4 New York Wiley
Armitage P, Berry G, Matthews JNS (2013) Statistical methods in medical research, 4th edn. Wiley, New York
38. Borm GF Fransen J Lemmens WAJG A simple sample size formula for analysis of covariance in randomized clinical trials J Clin Epidemiol 2007 60 1234 1238 10.1016/j.jclinepi.2007.02.006 17998077
Borm GF, Fransen J, Lemmens WAJG (2007) A simple sample size formula for analysis of covariance in randomized clinical trials. J Clin Epidemiol 60:1234–1238. 10.1016/j.jclinepi.2007.02.00617998077 10.1016/j.jclinepi.2007.02.006
39. Mersov AM Crane DE Chappell MA Estimating the sample size required to detect an arterial spin labelling magnetic resonance imaging perfusion abnormality in voxel-wise group analyses J Neurosci Methods 2015 245 169 177 10.1016/j.jneumeth.2015.02.017 25749568
Mersov AM, Crane DE, Chappell MA et al (2015) Estimating the sample size required to detect an arterial spin labelling magnetic resonance imaging perfusion abnormality in voxel-wise group analyses. J Neurosci Methods 245:169–177. 10.1016/j.jneumeth.2015.02.01725749568 10.1016/j.jneumeth.2015.02.017
40. Neergaard JS Dragsbæk K Christiansen C Metabolic syndrome, insulin resistance, and cognitive dysfunction: does your metabolic profile affect your brain? Diabetes 2017 66 1957 1963 10.2337/db16-1444 28389469
Neergaard JS, Dragsbæk K, Christiansen C et al (2017) Metabolic syndrome, insulin resistance, and cognitive dysfunction: does your metabolic profile affect your brain? Diabetes 66:1957–1963. 10.2337/db16-144428389469 10.2337/db16-1444
41. Biessels GJ Deary IJ Ryan CM Cognition and diabetes: a lifespan perspective Lancet Neurol 2008 7 184 190 10.1016/S1474-4422(08)70021-8 18207116
Biessels GJ, Deary IJ, Ryan CM (2008) Cognition and diabetes: a lifespan perspective. Lancet Neurol 7:184–190. 10.1016/S1474-4422(08)70021-818207116 10.1016/S1474-4422(08)70021-8
42. Gorelick PB Scuteri A Black SE Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association Stroke 2011 42 2672 2713 10.1161/STR.0b013e3182299496 21778438
Gorelick PB, Scuteri A, Black SE et al (2011) Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke 42:2672–2713. 10.1161/STR.0b013e318229949621778438 10.1161/STR.0b013e3182299496
43. van der Flier WM Skoog I Schneider JA Vascular cognitive impairment Nat Rev Dis Primers 2018 4 18003 10.1038/nrdp.2018.3 29446769
van der Flier WM, Skoog I, Schneider JA et al (2018) Vascular cognitive impairment. Nat Rev Dis Primers 4:18003. 10.1038/nrdp.2018.329446769 10.1038/nrdp.2018.3
44. Robbins TW James M Owen AM Cambridge Neuropsychological Test Automated Battery (CANTAB): a factor analytic study of a large sample of normal elderly volunteers Dementia 1994 5 266 281 10.1159/000106735 7951684
Robbins TW, James M, Owen AM et al (1994) Cambridge Neuropsychological Test Automated Battery (CANTAB): a factor analytic study of a large sample of normal elderly volunteers. Dementia 5:266–281. 10.1159/0001067357951684 10.1159/000106735
45. Mitchell AJ Beaumont H Ferguson D Risk of dementia and mild cognitive impairment in older people with subjective memory complaints: meta-analysis Acta Psychiatr Scand 2014 130 439 451 10.1111/acps.12336 25219393
Mitchell AJ, Beaumont H, Ferguson D et al (2014) Risk of dementia and mild cognitive impairment in older people with subjective memory complaints: meta-analysis. Acta Psychiatr Scand 130:439–451. 10.1111/acps.1233625219393 10.1111/acps.12336
46. Koepsell TD Monsell SE Reversion from mild cognitive impairment to normal or near-normal cognition: risk factors and prognosis Neurology 2012 79 1591 1598 10.1212/WNL.0b013e31826e26b7 23019264
Koepsell TD, Monsell SE (2012) Reversion from mild cognitive impairment to normal or near-normal cognition: risk factors and prognosis. Neurology 79:1591–1598. 10.1212/WNL.0b013e31826e26b723019264 10.1212/WNL.0b013e31826e26b7
47. Shigihara Y Hoshi H Shinada K Non-pharmacological treatment changes brain activity in patients with dementia Sci Rep 2020 10 6744 10.1038/s41598-020-63881-0 32317774
Shigihara Y, Hoshi H, Shinada K et al (2020) Non-pharmacological treatment changes brain activity in patients with dementia. Sci Rep 10:6744. 10.1038/s41598-020-63881-032317774 10.1038/s41598-020-63881-0
48. Conde DM Verdade RC Valadares ALR Menopause and cognitive impairment: a narrative review of current knowledge World J Psychiatry 2021 11 412 428 10.5498/wjp.v11.i8.412 34513605
Conde DM, Verdade RC, Valadares ALR et al (2021) Menopause and cognitive impairment: a narrative review of current knowledge. World J Psychiatry 11:412–428. 10.5498/wjp.v11.i8.41234513605 10.5498/wjp.v11.i8.412
49. Levine DA Gross AL Briceño EM Sex differences in cognitive decline among US adults JAMA Netw Open 2021 4 e210169 10.1001/jamanetworkopen.2021.0169 33630089
Levine DA, Gross AL, Briceño EM et al (2021) Sex differences in cognitive decline among US adults. JAMA Netw Open 4:e210169. 10.1001/jamanetworkopen.2021.016933630089 10.1001/jamanetworkopen.2021.0169
50. Carlson MC Xue Q-L Zhou J Executive decline and dysfunction precedes declines in memory: the women’s health and aging study II J Gerontol A Biol Sci Med Sci 2009 64 110 117 10.1093/gerona/gln008 19182230
Carlson MC, Xue Q-L, Zhou J et al (2009) Executive decline and dysfunction precedes declines in memory: the women’s health and aging study II. J Gerontol A Biol Sci Med Sci 64:110–117. 10.1093/gerona/gln00819182230 10.1093/gerona/gln008
51. Lee L Kang SA Lee HO Relationships between dietary intake and cognitive function level in Korean elderly people Public Health 2001 115 133 138 10.1038/sj.ph.1900729 11406779
Lee L, Kang SA, Lee HO et al (2001) Relationships between dietary intake and cognitive function level in Korean elderly people. Public Health 115:133–138. 10.1038/sj.ph.190072911406779 10.1038/sj.ph.1900729
52. Nes M Sem SW Rousseau B Dietary intakes and nutritional status of old people with dementia living at home in Oslo Eur J Clin Nutr 1988 42 581 593 3265665
Nes M, Sem SW, Rousseau B et al (1988) Dietary intakes and nutritional status of old people with dementia living at home in Oslo. Eur J Clin Nutr 42:581–5933265665
53. Ashburner J Friston KJ Voxel-based morphometry—the methods Neuroimage 2000 11 805 821 10.1006/nimg.2000.0582 10860804
Ashburner J, Friston KJ (2000) Voxel-based morphometry—the methods. Neuroimage 11:805–821. 10.1006/nimg.2000.058210860804 10.1006/nimg.2000.0582
54. Lefferts WK Augustine JA Spartano NL Effects of whey protein supplementation on aortic stiffness, cerebral blood flow, and cognitive function in community-dwelling older adults: findings from the ANCHORS A-WHEY clinical trial Nutrients 2020 12 1054 10.3390/nu12041054 32290271
Lefferts WK, Augustine JA, Spartano NL et al (2020) Effects of whey protein supplementation on aortic stiffness, cerebral blood flow, and cognitive function in community-dwelling older adults: findings from the ANCHORS A-WHEY clinical trial. Nutrients 12:1054. 10.3390/nu1204105432290271 10.3390/nu12041054
55. Kleinloog JPD Nijssen KMR Mensink RP Effects of physical exercise training on cerebral blood flow measurements: a systematic review of human intervention studies Int J Sport Nutr Exerc Metab 2023 33 47 59 10.1123/ijsnem.2022-0085 36170974
Kleinloog JPD, Nijssen KMR, Mensink RP et al (2023) Effects of physical exercise training on cerebral blood flow measurements: a systematic review of human intervention studies. Int J Sport Nutr Exerc Metab 33:47–59. 10.1123/ijsnem.2022-008536170974 10.1123/ijsnem.2022-0085
56. Nijssen KMR Mensink RP Plat J Longer-term mixed nut consumption improves brain vascular function and memory: a randomized, controlled crossover trial in older adults Clin Nutr 2023 42 1067 1075 10.1016/j.clnu.2023.05.025 37296019
Nijssen KMR, Mensink RP, Plat J et al (2023) Longer-term mixed nut consumption improves brain vascular function and memory: a randomized, controlled crossover trial in older adults. Clin Nutr 42:1067–1075. 10.1016/j.clnu.2023.05.02537296019 10.1016/j.clnu.2023.05.025
57. Banks WA Kastin AJ Passage of peptides across the blood-brain barrier: pathophysiological perspectives Life Sci 1996 59 1923 1943 10.1016/s0024-3205(96)00380-3 8950292
Banks WA, Kastin AJ (1996) Passage of peptides across the blood-brain barrier: pathophysiological perspectives. Life Sci 59:1923–1943. 10.1016/s0024-3205(96)00380-38950292 10.1016/s0024-3205(96)00380-3
58. Logue SF Gould TJ The neural and genetic basis of executive function: attention, cognitive flexibility, and response inhibition Pharmacol Biochem Behav 2014 123 45 54 10.1016/j.pbb.2013.08.007 23978501
Logue SF, Gould TJ (2014) The neural and genetic basis of executive function: attention, cognitive flexibility, and response inhibition. Pharmacol Biochem Behav 123:45–54. 10.1016/j.pbb.2013.08.00723978501 10.1016/j.pbb.2013.08.007
59. Margalef M Pons Z Iglesias-Carres L Gender-related similarities and differences in the body distribution of grape seed flavanols in rats Mol Nutr Food Res 2016 60 760 772 10.1002/mnfr.201500717 26799813
Margalef M, Pons Z, Iglesias-Carres L et al (2016) Gender-related similarities and differences in the body distribution of grape seed flavanols in rats. Mol Nutr Food Res 60:760–772. 10.1002/mnfr.20150071726799813 10.1002/mnfr.201500717
60. Flores K Manautou JE Renfro JL Gender-specific expression of ATP-binding cassette (Abc) transporters and cytoprotective genes in mouse choroid plexus Toxicology 2017 386 84 92 10.1016/j.tox.2017.05.019 28587784
Flores K, Manautou JE, Renfro JL (2017) Gender-specific expression of ATP-binding cassette (Abc) transporters and cytoprotective genes in mouse choroid plexus. Toxicology 386:84–92. 10.1016/j.tox.2017.05.01928587784 10.1016/j.tox.2017.05.019
61. Solarz A Majcher-Maślanka I Chocyk A Effects of early-life stress and sex on blood-brain barrier permeability and integrity in juvenile and adult rats Dev Neurobiol 2021 81 861 876 10.1002/dneu.22846 34320279
Solarz A, Majcher-Maślanka I, Chocyk A (2021) Effects of early-life stress and sex on blood-brain barrier permeability and integrity in juvenile and adult rats. Dev Neurobiol 81:861–876. 10.1002/dneu.2284634320279 10.1002/dneu.22846
62. Iadecola C The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia Acta Neuropathol 2010 120 287 296 10.1007/s00401-010-0718-6 20623294
Iadecola C (2010) The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathol 120:287–296. 10.1007/s00401-010-0718-620623294 10.1007/s00401-010-0718-6
63. de la Monte SM Insulin resistance and Alzheimer’s disease BMB Rep 2009 42 475 481 10.5483/bmbrep.2009.42.8.475 19712582
de la Monte SM (2009) Insulin resistance and Alzheimer’s disease. BMB Rep 42:475–481. 10.5483/bmbrep.2009.42.8.47519712582 10.5483/bmbrep.2009.42.8.475
64. Neumann KF Rojo L Navarrete LP Insulin resistance and Alzheimer’s disease: molecular links & clinical implications Curr Alzheimer Res 2008 5 438 447 10.2174/156720508785908919 18855585
Neumann KF, Rojo L, Navarrete LP et al (2008) Insulin resistance and Alzheimer’s disease: molecular links & clinical implications. Curr Alzheimer Res 5:438–447. 10.2174/15672050878590891918855585 10.2174/156720508785908919
65. Pugazhenthi S Qin L Reddy PH Common neurodegenerative pathways in obesity, diabetes, and Alzheimer’s disease Biochim Biophys Acta Mol Basis Dis 2017 1863 1037 1045 10.1016/j.bbadis.2016.04.017 27156888
Pugazhenthi S, Qin L, Reddy PH (2017) Common neurodegenerative pathways in obesity, diabetes, and Alzheimer’s disease. Biochim Biophys Acta Mol Basis Dis 1863:1037–1045. 10.1016/j.bbadis.2016.04.01727156888 10.1016/j.bbadis.2016.04.017
66. Kowiański P Lietzau G Czuba E BDNF: a key factor with multipotent impact on brain signaling and synaptic plasticity Cell Mol Neurobiol 2018 38 579 593 10.1007/s10571-017-0510-4 28623429
Kowiański P, Lietzau G, Czuba E et al (2018) BDNF: a key factor with multipotent impact on brain signaling and synaptic plasticity. Cell Mol Neurobiol 38:579–593. 10.1007/s10571-017-0510-428623429 10.1007/s10571-017-0510-4
67. Gravesteijn E Mensink RP Plat J Effects of nutritional interventions on BDNF concentrations in humans: a systematic review Nutr Neurosci 2022 25 1425 1436 10.1080/1028415X.2020.1865758 33427118
Gravesteijn E, Mensink RP, Plat J (2022) Effects of nutritional interventions on BDNF concentrations in humans: a systematic review. Nutr Neurosci 25:1425–1436. 10.1080/1028415X.2020.186575833427118 10.1080/1028415X.2020.1865758
68. Liu TT Brown GG Measurement of cerebral perfusion with arterial spin labeling: part 1 Methods J Int Neuropsychol Soc 2007 13 517 525 10.1017/S1355617707070646 17445301
Liu TT, Brown GG (2007) Measurement of cerebral perfusion with arterial spin labeling: part 1. Methods J Int Neuropsychol Soc 13:517–525. 10.1017/S135561770707064617445301 10.1017/S1355617707070646
69. Fan AP Jahanian H Holdsworth SJ Comparison of cerebral blood flow measurement with 15O-water positron emission tomography and arterial spin labeling magnetic resonance imaging: a systematic review J Cereb Blood Flow Metab 2016 36 842 861 10.1177/0271678X16636393 26945019
Fan AP, Jahanian H, Holdsworth SJ et al (2016) Comparison of cerebral blood flow measurement with 15O-water positron emission tomography and arterial spin labeling magnetic resonance imaging: a systematic review. J Cereb Blood Flow Metab 36:842–861. 10.1177/0271678X1663639326945019 10.1177/0271678X16636393
70. de Jager CA Dye L de Bruin EA Criteria for validation and selection of cognitive tests for investigating the effects of foods and nutrients Nutr Rev 2014 72 162 179 10.1111/nure.12094 24697324
de Jager CA, Dye L, de Bruin EA et al (2014) Criteria for validation and selection of cognitive tests for investigating the effects of foods and nutrients. Nutr Rev 72:162–179. 10.1111/nure.1209424697324 10.1111/nure.12094
71. Robbins TW James M Owen AM A study of performance on tests from the CANTAB battery sensitive to frontal lobe dysfunction in a large sample of normal volunteers: implications for theories of executive functioning and cognitive aging. Cambridge Neuropsychological Test Automated Battery J Int Neuropsychol Soc 1998 4 474 490 10.1017/s1355617798455073 9745237
Robbins TW, James M, Owen AM et al (1998) A study of performance on tests from the CANTAB battery sensitive to frontal lobe dysfunction in a large sample of normal volunteers: implications for theories of executive functioning and cognitive aging. Cambridge Neuropsychological Test Automated Battery. J Int Neuropsychol Soc 4:474–490. 10.1017/s13556177984550739745237 10.1017/s1355617798455073
72. Louis WJ Mander AG Dawson M Use of computerized neuropsychological tests (CANTAB) to assess cognitive effects of antihypertensive drugs in the elderly. Cambridge Neuropsychological Test Automated Battery J Hypertens 1999 17 1813 1819 10.1097/00004872-199917121-00005 10703873
Louis WJ, Mander AG, Dawson M et al (1999) Use of computerized neuropsychological tests (CANTAB) to assess cognitive effects of antihypertensive drugs in the elderly. Cambridge Neuropsychological Test Automated Battery. J Hypertens 17:1813–1819. 10.1097/00004872-199917121-0000510703873 10.1097/00004872-199917121-00005
